血液稀释对急性髓系白血病流式细胞术可测量残留病评估的影响
该前瞻性研究在急性髓系白血病患者中连续三次抽取2 mL骨髓液并同步采集外周血,发现骨髓可测量残留病(MRD)百分比从第一管到第二管(P=0.025)、第二管到第三管(P=0.025)显著下降,超过0.1%阈值的MRD比例从39%(18/46)降至第三管的30%(14/46);研究评估了六种区分骨髓与外周血的方法,其中CD16dim粒细胞群和CD117high肥大细胞百分比最有前景。
要点
- 连续骨髓抽取中MRD百分比逐管显著下降,提示血液稀释可致假阴性。
- 超过0.1%阈值的MRD比例从第一管39%(18/46)降至第三管30%(14/46)。
- CD16dim粒细胞和CD117high肥大细胞百分比是区分骨髓与外周血最有前景的参数。
核心结论
- 血液稀释会显著降低骨髓MRD检出百分比,尤其在0.1%阈值附近可能造成假阴性。
- 为避免血液稀释所致假阴性,应采集高质量骨髓并优先使用第一管抽取液进行MRD检测。
研究设计与样本
- 前瞻性研究,对急性髓系白血病患者连续三次抽取2 mL骨髓液并同步采集外周血样本。
- 共评估46种白血病相关免疫表型(18/46、14/46等)及六种已发表区分骨髓与外周血的方法和参数。
主要发现
- MRD百分比在第一管与第二管之间(P=0.025)及第二管与第三管之间(P=0.025)显著下降。
- 超过0.1%阈值的MRD比例从第一管的39%(18/46)降至第三管的30%(14/46)。
- 区分骨髓与外周血最有前景的参数为CD16dim粒细胞群百分比(骨髓中稀少)和CD117high肥大细胞百分比(骨髓独有)。
关键数值与推荐
- MRD超过0.1%阈值的比例:第一管39%(18/46) vs 第三管30%(14/46)。
- 第一管与第二管MRD百分比比较P=0.025;第二管与第三管比较P=0.025。
临床怎么用
- 作者认为,为评估MRD结果尤其接近常用0.1%阈值时,应估计血液稀释的影响。
- 作者建议,为避免血液稀释导致假阴性,应采集高质量骨髓抽取液并优先使用第一管进行MRD检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Measurable residual disease (MRD) measured in the bone marrow (BM) of acute myeloid leukemia (AML) patients after induction chemotherapy is an established prognostic factor. Hemodilution, stemming from peripheral blood (PB) mixing within BM during aspiration, can yield false-negative MRD results. We prospectively examined hemodilution by measuring MRD in BM aspirates obtained from three consecutive 2 mL pulls, along with PB samples. Our results demonstrated a significant decrease in MRD percentages between the first and second pulls (P = 0.025) and between the second and third pulls (P = 0.025), highlighting the impact of hemodilution. Initially, 39% of MRD levels (18/46 leukemia-associated immunophenotypes) exceeded the 0.1% cut-off, decreasing to 30% (14/46) in the third pull. Additionally, we assessed the performance of six published methods and parameters for distinguishing BM from PB samples, addressing or compensating for hemodilution. The most promising results relied on the percentages of CD16dim granulocytic population (scarce in BM) and CD117high mast cells (exclusive to BM). Our findings highlight the importance of estimating hemodilution in MRD assessment to qualify MRD results, particularly near the common 0.1% cut-off. To avoid false-negative results by hemodilution, it is essential to collect high-quality BM aspirations and preferably utilizing the initial pull for MRD testing.
引用
- Tettero JM, Heidinga ME, Mocking TR, et al. Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia. Leukemia. 2024. PMID: 38272991. doi:10.1038/s41375-024-02158-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。